Overview
Description
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for breast cancer and other breast conditions. The primary aim of Atossa Therapeutics is to advance healthcare solutions through its proprietary therapies that target significant unmet medical needs related to breast health. Atossa develops both oral and topical treatments designed to improve outcomes and experiences for patients undergoing various stages of breast cancer treatment, as well as preventive measures for high-risk patients. One of the company's notable approaches involves utilizing molecular and genetic analysis to tailor personalized medicine. Atossa Therapeutics operates in the dynamic biotechnology sector, contributing to advancements in oncology, specifically in hormone receptor-positive and triple-negative breast cancers. Its research and development efforts hold potential implications for the pharmaceutical industry, offering novel therapeutic options that could enhance standards of care. Established in Seattle, Washington, Atossa continues to play a key role in the biopharmaceutical market by championing the development of targeted therapies, underscoring the importance of innovation in tackling complex health challenges.
About
CEO
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Employees
15
Address
107 Spring Street
Seattle, 98104, WA
United States
Seattle, 98104, WA
United States
Phone
206-588-0256
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Germany
MIC code
XFRA